Q-omics provides the consensus-scored THEM4 profile across patient tissues and cancer cell-line models. THEM4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, THEM4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, THEM4 RNA expression shows 19,476 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where THEM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THEM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THEM4 survival associations across molecular data types. THEM4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THEM4 RNA expression–survival associations across cancer types. High THEM4 expression shows unfavorable associations in LIHC, KIRP and STAD, but favorable associations in PAAD, READ and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for THEM4 RNA expression.
This table summarizes THEM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THEM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THEM4 shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, LIHC, STAD and LUAD. The HNSC box plot shows higher THEM4 RNA expression in tumor versus normal tissue (log2 FC = +0.709, t-test p < 0.001).
This table shows molecular features associated with THEM4 in patient tissues and cancer cell lines. In patient samples, THEM4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, THEM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
